<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">40126</article-id><article-id pub-id-type="doi">10.7554/eLife.40126</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>TAPBPR mediates peptide dissociation from MHC class I using a leucine lever</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-118005"><name><surname>Ilca</surname><given-names>Florin Tudor</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6582-8007</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-37224"><name><surname>Neerincx</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-37221"><name><surname>Hermann</surname><given-names>Clemens</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-118029"><name><surname>Marcu</surname><given-names>Ana</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0808-8097</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-118006"><name><surname>Stefvanovic</surname><given-names>Stefan</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15515"><name><surname>Deane</surname><given-names>Janet E</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4863-0330</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-36640"><name><surname>Boyle</surname><given-names>Louise H</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3105-6555</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf4"/></contrib><aff id="aff1"><institution content-type="dept">Department of Pathology</institution>, <institution>University of Cambridge</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff2"><institution content-type="dept">Department of Integrative Biomedical Sciences, Division of Chemical and Systems Biology, Institute for Infectious Disease and Molecular Medicine</institution>, <institution>University of Cape Town</institution>, <addr-line><named-content content-type="city">Cape Town</named-content></addr-line>, <country>South Africa</country></aff><aff id="aff3"><institution content-type="dept">Interfaculty Institute for Cell Biology, Department of Immunology</institution>, <institution>University of Tübingen</institution>, <addr-line><named-content content-type="city">Tübingen</named-content></addr-line>, <country>Germany</country></aff><aff id="aff4"><institution content-type="dept">Cambridge Institute for Medical Research</institution>, <institution>University of Cambridge</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-28049"><name><surname>Wucherpfennig</surname><given-names>Kai</given-names></name><role>Reviewing editor</role><aff><country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>lhb22@cam.ac.uk</email> (LB);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>28</day><month>11</month><year>2018</year></pub-date><volume>7</volume><elocation-id>e40126</elocation-id><history><date date-type="received"><day>15</day><month>07</month><year>2018</year></date><date date-type="accepted"><day>28</day><month>11</month><year>2018</year></date></history><permissions><copyright-statement>© 2018, Ilca et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Ilca et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-40126-v1.pdf"/><abstract><p>Tapasin and TAPBPR are known to perform peptide editing on major histocompatibility complex class I (MHC I) molecules, however, the precise molecular mechanism(s) involved in this process remain largely enigmatic. Here, using immunopeptidomics in combination with novel cell-based assays that assess TAPBPR-mediate peptide exchange, we reveal a critical role for the K22-D35 loop of TAPBPR in mediating peptide exchange on MHC I. We identify a specific leucine within this loop that enables TAPBPR to facilitate peptide dissociation from MHC I. Moreover, we delineate the molecular features of the MHC I F pocket required for TAPBPR to promote peptide dissociation in a loop-dependent manner. These data reveal that chaperone-mediated peptide editing of MHC I can occur by different mechanisms dependent on the C-terminal residue that the MHC I accommodates in its F pocket and provide novel insights that may inform the therapeutic potential of TAPBPR manipulation to increase tumour immunogenicity.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome</institution></institution-wrap></funding-source><award-id>104647/Z/14/Z</award-id><principal-award-recipient><name><surname>Neerincx</surname><given-names>Andreas</given-names></name><name><surname>Boyle</surname><given-names>Louise H</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001322</institution-id><institution>South African Medical Research Council</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Hermann</surname><given-names>Clemens</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000288</institution-id><institution>Royal Society</institution></institution-wrap></funding-source><award-id>UF100371</award-id><principal-award-recipient><name><surname>Deane</surname><given-names>Janet E</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution>Bosch-Forschungsstiftung</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Marcu</surname><given-names>Ana</given-names></name><name><surname>Stefvanovic</surname><given-names>Stefan</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome</institution></institution-wrap></funding-source><award-id>109076/Z/15/A</award-id><principal-award-recipient><name><surname>Ilca</surname><given-names>Florin Tudor</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Florin Tudor Ilca, Some aspects of the work included in this manuscript form part of a recent patent application. Applicant: Cambridge Enterprise Limited. Application number: 1801323.5, Status: Pending.</p></fn><fn fn-type="conflict" id="conf3"><p>Andreas Neerincx, Some aspects of the work included in this manuscript form part of a recent patent application. Applicant: Cambridge Enterprise Limited. Application number: 1801323.5, Status: Pending.</p></fn><fn fn-type="conflict" id="conf4"><p>Louise H Boyle, Some aspects of the work included in this manuscript form part of a recent patent application. Applicant: Cambridge Enterprise Limited. Application number: 1801323.5, Status: Pending.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files. Source data files regarding the lists of peptides presented on MHC class I have been provided for Figures 5</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Ilca FT</collab><collab>Neerincx A</collab><collab>Hermann C</collab><collab>Marcu A</collab><collab>Stevanovic S</collab><collab>Deane JE</collab><collab>Boyle LH</collab></person-group><year iso-8601-date="2018">2018</year><source>Data from: TAPBPR mediates peptide dissociation from MHC class I using a leucine lever</source><ext-link ext-link-type="uri" xlink:href="https://dx.doi.org/10.5061/dryad.p5k0156">https://dx.doi.org/10.5061/dryad.p5k0156</ext-link><comment>Dryad, doi:10.5061/dryad.p5k0156</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-40126-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>